Erstes Halbjahr mit 1%1  Wachstum zu konstanten Wechselkursen, starker Einfluss der Covid-19- Pandemie  

NEXT STORY
Prospective Study Finds Potential Utility of MeMed’s Host Immune Technology for Personalizing Treatment of Severe COVID-19 Patients
PREV STORY
BioNTech Announces Pricing of Upsized Underwritten Offering and Terms of Rights Offering
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Publishing of Orion Corporation’s Half-Year Financial Report for January-June 2018 on 18 July 2018

ORION CORPORATION                     PRESS RELEASE                   5 JULY 2018 at 11.30 EESTPublishing of Orion Corporation's Half-Year ...

author_avatar
NASDAQ Market News

Argos Therapeutics Announces Closing of $6.0 Million Secured Convertible Note Financing

DURHAM, N.C., June 22, 2017 (GLOBE NEWSWIRE) -- Argos Therapeutics, Inc. (Nasdaq:ARGS), an immuno-oncology ...

author_avatar
NASDAQ Market News

OLYSIO® sales during the first quarter 2016

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announces that the global first ...

author_avatar
NASDAQ Market News